Journal
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Volume 18, Issue 6, Pages 593-599Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737167.2018.1505505
Keywords
Liquid biopsies; cancer; circulating tumor cells; ctDNA; health economics; biomarker; diagnostic
Funding
- EU [FP7 HEALTH.2012.1.2-1, 305341 CTCTrap]
- EU-FP7 grant (CTC-TRAP)
- Experimental Cancer Medicine Centre
- Cancer Research UK Centre
- November Prostate Cancer Centre of Excellence
Ask authors/readers for more resources
Introduction: Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed. Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. We conclude with a future perspective on the clinical use and reimbursement of LBs Expert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits. This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available